- Home
- NVCR vs ZYME Comparison
NVCR vs ZYME Comparison
Compare NVCR & ZYME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NVCR
- ZYME
- Stock Information
- Founded
- NVCR 2000
- ZYME 2003
- Country
- NVCR Switzerland
- ZYME United States
- Employees
- NVCR N/A
- ZYME N/A
- Industry
- NVCR Medical/Dental Instruments
- ZYME Biotechnology: Pharmaceutical Preparations
- Sector
- NVCR Health Care
- ZYME Health Care
- Exchange
- NVCR Nasdaq
- ZYME Nasdaq
- Market Cap
- NVCR 1.4B
- ZYME 1.2B
- IPO Year
- NVCR 2015
- ZYME 2017
- Fundamental
- Price
- NVCR $14.04
- ZYME $16.56
- Analyst Decision
- NVCR Buy
- ZYME Buy
- Analyst Count
- NVCR 7
- ZYME 7
- Target Price
- NVCR $28.79
- ZYME $20.00
- AVG Volume (30 Days)
- NVCR 1.9M
- ZYME 648.0K
- Earning Date
- NVCR 10-30-2025
- ZYME 10-30-2025
- Dividend Yield
- NVCR N/A
- ZYME N/A
- EPS Growth
- NVCR N/A
- ZYME N/A
- EPS
- NVCR N/A
- ZYME N/A
- Revenue
- NVCR $630,160,000.00
- ZYME $122,867,000.00
- Revenue This Year
- NVCR $6.68
- ZYME $107.76
- Revenue Next Year
- NVCR $7.01
- ZYME $2.35
- P/E Ratio
- NVCR N/A
- ZYME N/A
- Revenue Growth
- NVCR 14.58
- ZYME 95.94
- 52 Week Low
- NVCR $10.87
- ZYME $9.03
- 52 Week High
- NVCR $34.13
- ZYME $17.70
- Technical
- Relative Strength Index (RSI)
- NVCR 60.46
- ZYME 57.31
- Support Level
- NVCR $12.61
- ZYME $16.75
- Resistance Level
- NVCR $14.77
- ZYME $17.40
- Average True Range (ATR)
- NVCR 0.55
- ZYME 0.58
- MACD
- NVCR 0.19
- ZYME -0.06
- Stochastic Oscillator
- NVCR 67.68
- ZYME 38.20
About NVCR NovoCure Limited
NovoCure Ltd is an oncology company with a propreitary platform technology in United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.
About ZYME Zymeworks Inc.
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.